Year: 2018
Type: editorial
Abstract: a key driver for the clinical development of oritavancin was the promise of a drug that would permit the discharge of patients and save costs associated with hospitalization "
Source: Future Microbiology
Authors: Greta Flüh, Harald Seifert, Achim J Kaasch
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2804870902